Human Vaccines & Immunotherapeutics · 2013 · 40 citations · 19 references
Life SciencesBiotechnologyInfectious DiseasesProtein EngineeringVaccine BiotechnologyVaccinologyHelminth PathogenesisProtein Expression EngineeringRecombinant Protein ProductionRecombinant Protein VaccinesRecombinant Vaccine DevelopmentVaccine Antigen DiscoveryPathogenesis Of SchistosomiasisProtein Purity AssessmentProtein RecoveryProtein Subunit Vaccine FormulationsProtein Yield AssessmentPurification Of Vaccine AntigensRecombinant Protein RecoveryRecovery Yield
A novel recombinant protein vaccine for human schistosomiasis caused by Schistosoma mansoni is under development. The Sm-TSP-2 schistosomiasis vaccine is comprised of a 9 kDa recombinant protein corresponding to the extracellular domain of a unique S. mansoni tetraspanin. Here, we describe the cloning and the expression of the external loop of Sm-TSP-2 recombinant protein secreted by Pichia Pink the process development at 20L scale fermentation, and the two-steps purification, which resulted in a protein recovery yield of 31% and a protein purity of 97%. The developed processes are suitable for the production of purified protein for subsequent formulation and Phase 1 clinical studies.
19
The global status of schistosomiasis and its control
Lester Chitsulo, Dirk Engels, Antonio Montresor et al. · Acta Tropica · 2000 · 1.4K citations · Full text
Veterinary Medicine, Infectious Disease Control, Infectious Diseases +12
The genome of the blood fluke Schistosoma mansoni
Matthew Berriman, Brian J. Haas, Philip T. LoVerde et al. · Nature · 2009 · 1.1K citations · Full text